| 8 mg/kg Tocilizumab + methotrexate | 4 mg/kg Tocilizumab + methotrexate | Placebo + methotrexate | |
| ACR response by most recently failed anti-TNF treatment; n/n′ (% responders) | |||
| ACR20 | |||
| Etanercept | 35/67 (52.2%) | 17/61 (27.9%) | 8/49 (16.3%) |
| Adalimumab | 26/49 (53.1%) | 19/55 (34.5%) | 3/62 (4.8%) |
| Infliximab | 24/54 (44.4%) | 13/43 (30.2%) | 5/47 (10.6%) |
| ACR50 | |||
| Etanercept | 19/67 (28.4%) | 6/61 (9.8%) | 3/49 (6.1%) |
| Adalimumab | 19/49 (38.8%) | 13/55 (23.6%) | 0/62 (0.0%) |
| Infliximab | 11/54 (20.4%) | 8/43 (18.6%) | 3/47 (6.4%) |
| ACR70 | |||
| Etanercept | 10/67 (14.9%) | 0/61 (0.0%) | 1/49 (2.0%) |
| Adalimumab | 6/49 (12.2%) | 5/55 (9.1%) | 0/62 (0.0%) |
| Infliximab | 5/54 (9.3%) | 3/43 (7.0%) | 1/47 (2.1%) |
| ACR response by number of previous anti-TNF treatments; n/n′ (% responders) | |||
| ACR20 | |||
| One | 45/92 (48.9%) | 28/81 (34.6%) | 8/76 (10.5%) |
| Two | 26/52 (50.0%) | 17/60 (28.3%) | 7/64 (10.9%) |
| Three | 14/26 (53.8%) | 4/18 (22.2%) | 1/18 (5.6%) |
| ACR50 | |||
| One | 28/92 (30.4%) | 15/81 (18.5%) | 5/76 (6.6%) |
| Two | 16/52 (30.8%) | 8/60 (13.3%) | 1/64 (1.6%) |
| Three | 5/26 (19.2%) | 4/18 (22.2%) | 0/18 (0.0%) |
| ACR70 | |||
| One | 11/92 (12.0%) | 6/81 (7.4%) | 2/76 (2.6%) |
| Two | 8/52 (15.4%) | 2/60 (3.3%) | 0/64 (0.0%) |
| Three | 2/26 (7.7%) | 0/18 (0.0%) | 0/18 (0.0%) |
n, number of patients with ACR response; n′, total number of patients in group; TNF, tumour necrosis factor.